ROFACT DIN 00343617
Health Canada record
| Active ingredient(s) | RIFAMPIN 300 MG |
|---|---|
| Dosage form | Capsule |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | J04AB02 RIFAMPICIN |
| Original market date | 31-Dec-1977 |
| Current status date | 02-Jul-2019 |
| Source | Health Canada DPD |
Establishment licence of the holder
Bausch Health Companies Inc. — licence 101880, currently licensed, last inspection rating C (2026-06-01).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing RIFAMPIN
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 00393444 | ROFACT | BAUSCH HEALTH, CANADA INC. | Capsule | RIFAMPIN 150 MG | Marketed |
| 02091887 | RIFADIN | SANOFI-AVENTIS CANADA INC | Capsule | RIFAMPIN 150 MG | Cancelled Post Market |
| 02092808 | RIFADIN | SANOFI-AVENTIS CANADA INC | Capsule | RIFAMPIN 300 MG | Cancelled Post Market |
| 00580384 | RIFADIN CAP 300MG | MERRELL DOW PHARMACEUTICALS (CANADA) INC., DIVISION OF MMDC | Capsule | RIFAMPIN 300 MG | Cancelled Post Market |
| 02148625 | RIFATER | SANOFI-AVENTIS CANADA INC | Tablet | RIFAMPIN 120 MG; ISONIAZID 50 MG; PYRAZINAMIDE 300 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 22355 | 2019-07-02 | New Drug Submission (NDS) | Administrative: Change in Product Ownership |
| 5354 | 2004-09-14 | New Drug Submission (NDS) | MANUFACTURER NAME CHANGE |
International API supply for RIFAMPIN
4 active FDA Drug Master Files.
Request a quote for ROFACT